Skip to main content
Erschienen in: Tumor Biology 3/2016

16.10.2015 | Original Article

Immunophenotyping of patients with oral squamous cell carcinoma in peripheral blood and associated tumor tissue

verfasst von: Martin Grimm, Oliver Feyen, Heiko Hofmann, Peter Teriete, Thorsten Biegner, Adelheid Munz, Siegmar Reinert

Erschienen in: Tumor Biology | Ausgabe 3/2016

Einloggen, um Zugang zu erhalten

Abstract

The immune system is important for elimination of cancer cells. Tumors including oral squamous cell carcinoma (OSCC) are capable of escaping detection by host immune cells through apoptotic depletion of tumor-infiltrating lymphocytes (TILs). Circulating peripheral blood lymphocytes (PBLs) and corresponding TILs of tumor specimen were evaluated before and after curative tumor resection (n = 30) compared with PBLs of controls (n = 87). PBLs were characterized for the total number of T cells (CD3+), T helper cells (Th, CD3+/CD4+), regulatory T cells (Treg, CD4+/CD25+/CD127low), cytotoxic T cells (Tc, CD3+/CD8+), activated T cells (CD3+/HLA-DR+), and natural killer (NK) cells (CD3/CD16+/CD56+). In tumor tissue, the prevalence of CD3+, CD4+, and CD8+ TILs was assessed using immunohistochemistry, whereas the incidence of apoptosis was assessed using terminal deoxynucleotidyl transferase deoxyuridinetriphosphate nick-end labeling (TUNEL) assay. In PBLs of pretreated OSCC patients, a highly significant decrease in total number of T cells (p = 0.0001), Th cells (p < 0.0001), Treg cells (p < 0.0001), Tc cells (p < 0.0001), and NK cells (p = 0.0037) were found compared with controls. Decreased PBLs of OSCC patients were correlated with decreased numbers of corresponding TILs, which were associated with increased detection of apoptosis in the tumor tissue. Compared with the controls, the total number of T cells remained unchanged after surgery but the total number of NK cells significantly increased. Standardized immunophenotyping of OSCC may help to identify patients likely to benefit from cancer immunotherapy strategies and/or chemoradiation. Finally, future attempts to enhance an effective tumor-reactive immune response by immunotherapy or vaccination should be made by promoting tumor-specific Th and/or Tc cell/NK cell responses.
Literatur
2.
Zurück zum Zitat Badoual C, Sandoval F, Pere H, Hans S, Gey A, Merillon N, et al. Better understanding tumor-host interaction in head and neck cancer to improve the design and development of immunotherapeutic strategies. Head Neck. 2010;32(7):946–58. doi:10.1002/hed.21346.PubMed Badoual C, Sandoval F, Pere H, Hans S, Gey A, Merillon N, et al. Better understanding tumor-host interaction in head and neck cancer to improve the design and development of immunotherapeutic strategies. Head Neck. 2010;32(7):946–58. doi:10.​1002/​hed.​21346.PubMed
8.
Zurück zum Zitat Tanaka H, Yoshizawa H, Yamaguchi Y, Ito K, Kagamu H, Suzuki E, et al. Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells. J Immunol. 1999;162(6):3574–82.PubMed Tanaka H, Yoshizawa H, Yamaguchi Y, Ito K, Kagamu H, Suzuki E, et al. Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells. J Immunol. 1999;162(6):3574–82.PubMed
10.
Zurück zum Zitat Igney FH, Krammer PH. Immune escape of tumors: apoptosis resistance and tumor counterattack. J Leukoc Biol. 2002;71(6):907–20.PubMed Igney FH, Krammer PH. Immune escape of tumors: apoptosis resistance and tumor counterattack. J Leukoc Biol. 2002;71(6):907–20.PubMed
11.
Zurück zum Zitat Gastman BR, Atarshi Y, Reichert TE, Saito T, Balkir L, Rabinowich H, et al. Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes. Cancer Res. 1999;59(20):5356–64.PubMed Gastman BR, Atarshi Y, Reichert TE, Saito T, Balkir L, Rabinowich H, et al. Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes. Cancer Res. 1999;59(20):5356–64.PubMed
12.
13.
Zurück zum Zitat Reichert TE, Strauss L, Wagner EM, Gooding W, Whiteside TL. Signaling abnormalities, apoptosis, and reduced proliferation of circulating and tumor-infiltrating lymphocytes in patients with oral carcinoma. Clin Cancer Res. 2002;8(10):3137–45.PubMed Reichert TE, Strauss L, Wagner EM, Gooding W, Whiteside TL. Signaling abnormalities, apoptosis, and reduced proliferation of circulating and tumor-infiltrating lymphocytes in patients with oral carcinoma. Clin Cancer Res. 2002;8(10):3137–45.PubMed
14.
Zurück zum Zitat Kim JW, Wieckowski E, Taylor DD, Reichert TE, Watkins S, Whiteside TL. Fas ligand-positive membranous vesicles isolated from sera of patients with oral cancer induce apoptosis of activated T lymphocytes. Clin Cancer Res. 2005;11(3):1010–20.PubMed Kim JW, Wieckowski E, Taylor DD, Reichert TE, Watkins S, Whiteside TL. Fas ligand-positive membranous vesicles isolated from sera of patients with oral cancer induce apoptosis of activated T lymphocytes. Clin Cancer Res. 2005;11(3):1010–20.PubMed
15.
Zurück zum Zitat Hoffmann TK, Dworacki G, Tsukihiro T, Meidenbauer N, Gooding W, Johnson JT, et al. Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance. Clin Cancer Res. 2002;8(8):2553–62.PubMed Hoffmann TK, Dworacki G, Tsukihiro T, Meidenbauer N, Gooding W, Johnson JT, et al. Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance. Clin Cancer Res. 2002;8(8):2553–62.PubMed
16.
Zurück zum Zitat Wolf GT, Hudson JL, Peterson KA, Miller HL, McClatchey KD. Lymphocyte subpopulations infiltrating squamous carcinomas of the head and neck: correlations with extent of tumor and prognosis. Otolaryngol Head Neck Surg. 1986;95(2):142–52.CrossRefPubMed Wolf GT, Hudson JL, Peterson KA, Miller HL, McClatchey KD. Lymphocyte subpopulations infiltrating squamous carcinomas of the head and neck: correlations with extent of tumor and prognosis. Otolaryngol Head Neck Surg. 1986;95(2):142–52.CrossRefPubMed
17.
Zurück zum Zitat Wolf GT, Schmaltz S, Hudson J, Robson H, Stackhouse T, Peterson KA, et al. Alterations in T-lymphocyte subpopulations in patients with head and neck cancer. Correlations with prognosis. Arch Otolaryngol Head Neck Surg. 1987;113(11):1200–6.CrossRefPubMed Wolf GT, Schmaltz S, Hudson J, Robson H, Stackhouse T, Peterson KA, et al. Alterations in T-lymphocyte subpopulations in patients with head and neck cancer. Correlations with prognosis. Arch Otolaryngol Head Neck Surg. 1987;113(11):1200–6.CrossRefPubMed
19.
Zurück zum Zitat Balermpas P, Michel Y, Wagenblast J, Seitz O, Weiss C, Rodel F, et al. Tumour-infiltrating lymphocytes predict response to definitive chemoradiotherapy in head and neck cancer. Br J Cancer. 2014;110(2):501–9. doi:10.1038/bjc.2013.640.CrossRefPubMed Balermpas P, Michel Y, Wagenblast J, Seitz O, Weiss C, Rodel F, et al. Tumour-infiltrating lymphocytes predict response to definitive chemoradiotherapy in head and neck cancer. Br J Cancer. 2014;110(2):501–9. doi:10.​1038/​bjc.​2013.​640.CrossRefPubMed
21.
Zurück zum Zitat Gaur P, Qadir GA, Upadhyay S, Singh AK, Shukla NK, Das SN. Skewed immunological balance between Th17 (CD4(+)IL17A (+)) and Treg (CD4 (+)CD25 (+)FOXP3 (+)) cells in human oral squamous cell carcinoma. Cell Oncol (Dordr). 2012;35(5):335–43. doi:10.1007/s13402-012-0093-5.CrossRef Gaur P, Qadir GA, Upadhyay S, Singh AK, Shukla NK, Das SN. Skewed immunological balance between Th17 (CD4(+)IL17A (+)) and Treg (CD4 (+)CD25 (+)FOXP3 (+)) cells in human oral squamous cell carcinoma. Cell Oncol (Dordr). 2012;35(5):335–43. doi:10.​1007/​s13402-012-0093-5.CrossRef
22.
Zurück zum Zitat Gasparoto TH, de Souza Malaspina TS, Benevides L, de Melo EJ, Costa Jr MR, Damante JH, et al. Patients with oral squamous cell carcinoma are characterized by increased frequency of suppressive regulatory T cells in the blood and tumor microenvironment. Journal of the Formosan immunol, immunother: CII. 2010;59(6):819–28. doi:10.1007/s00262-009-0803-7.CrossRef Gasparoto TH, de Souza Malaspina TS, Benevides L, de Melo EJ, Costa Jr MR, Damante JH, et al. Patients with oral squamous cell carcinoma are characterized by increased frequency of suppressive regulatory T cells in the blood and tumor microenvironment. Journal of the Formosan immunol, immunother: CII. 2010;59(6):819–28. doi:10.​1007/​s00262-009-0803-7.CrossRef
26.
Zurück zum Zitat Drennan S, Stafford ND, Greenman J, Green VL. Increased frequency and suppressive activity of CD127(low/-) regulatory T cells in the peripheral circulation of patients with head and neck squamous cell carcinoma are associated with advanced stage and nodal involvement. Immunology. 2013;140(3):335–43. doi:10.1111/imm.12144.PubMedPubMedCentral Drennan S, Stafford ND, Greenman J, Green VL. Increased frequency and suppressive activity of CD127(low/-) regulatory T cells in the peripheral circulation of patients with head and neck squamous cell carcinoma are associated with advanced stage and nodal involvement. Immunology. 2013;140(3):335–43. doi:10.​1111/​imm.​12144.PubMedPubMedCentral
27.
Zurück zum Zitat Rammensee HG, Weinschenk T, Gouttefangeas C, Stevanovic S. Towards patient-specific tumor antigen selection for vaccination. Immunol Rev. 2002;188:164–76.CrossRefPubMed Rammensee HG, Weinschenk T, Gouttefangeas C, Stevanovic S. Towards patient-specific tumor antigen selection for vaccination. Immunol Rev. 2002;188:164–76.CrossRefPubMed
28.
Zurück zum Zitat Singh-Jasuja H, Emmerich NP, Rammensee HG. The Tubingen approach: identification, selection, and validation of tumor-associated HLA peptides for cancer therapy. Cancer immunology, immunotherapy : CII. 2004;53(3):187–95. doi:10.1007/s00262-003-0480-x.CrossRefPubMed Singh-Jasuja H, Emmerich NP, Rammensee HG. The Tubingen approach: identification, selection, and validation of tumor-associated HLA peptides for cancer therapy. Cancer immunology, immunotherapy : CII. 2004;53(3):187–95. doi:10.​1007/​s00262-003-0480-x.CrossRefPubMed
29.
Zurück zum Zitat Feyen O, Coy JF, Prasad V, Schierl R, Saenger J, Baum RP. EDIM-TKTL1 blood test: a noninvasive method to detect upregulated glucose metabolism in patients with malignancies. Future Oncol. 2012;8(10):1349–59. doi:10.2217/fon.12.98.CrossRefPubMed Feyen O, Coy JF, Prasad V, Schierl R, Saenger J, Baum RP. EDIM-TKTL1 blood test: a noninvasive method to detect upregulated glucose metabolism in patients with malignancies. Future Oncol. 2012;8(10):1349–59. doi:10.​2217/​fon.​12.​98.CrossRefPubMed
30.
Zurück zum Zitat Grimm M, Cetindis M, Lehmann M, Biegner T, Munz A, Teriete P, et al. Association of cancer metabolism-related proteins with oral carcinogenesis—indications for chemoprevention and metabolic sensitizing of oral squamous cell carcinoma? J Transl Med. 2014;12:208. doi:10.1186/1479-5876-12-208.CrossRefPubMedPubMedCentral Grimm M, Cetindis M, Lehmann M, Biegner T, Munz A, Teriete P, et al. Association of cancer metabolism-related proteins with oral carcinogenesis—indications for chemoprevention and metabolic sensitizing of oral squamous cell carcinoma? J Transl Med. 2014;12:208. doi:10.​1186/​1479-5876-12-208.CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem. 1993;39(4):561–77.PubMed Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem. 1993;39(4):561–77.PubMed
35.
Zurück zum Zitat Ostrand-Rosenberg S. CD4+ T lymphocytes: a critical component of antitumor immunity. Cancer Invest. 2005;23(5):413–9.PubMed Ostrand-Rosenberg S. CD4+ T lymphocytes: a critical component of antitumor immunity. Cancer Invest. 2005;23(5):413–9.PubMed
36.
37.
Zurück zum Zitat Timar J, Ladanyi A, Forster-Horvath C, Lukits J, Dome B, Remenar E, et al. Neoadjuvant immunotherapy of oral squamous cell carcinoma modulates intratumoral CD4/CD8 ratio and tumor microenvironment: a multicenter phase II clinical trial. J Clin Oncol. 2005;23(15):3421–32. doi:10.1200/JCO.2005.06.005.CrossRefPubMed Timar J, Ladanyi A, Forster-Horvath C, Lukits J, Dome B, Remenar E, et al. Neoadjuvant immunotherapy of oral squamous cell carcinoma modulates intratumoral CD4/CD8 ratio and tumor microenvironment: a multicenter phase II clinical trial. J Clin Oncol. 2005;23(15):3421–32. doi:10.​1200/​JCO.​2005.​06.​005.CrossRefPubMed
38.
Zurück zum Zitat Yeh CY, Lin CL, Chang MC, Chen HM, Kok SH, Chang SH, et al. Differences in oral habit and lymphocyte subpopulation affect malignant transformation of patients with oral precancer. J Formos Med Assoc=Taiwan yi zhi. 2015. doi:10.1016/j.jfma.2015.07.017. Yeh CY, Lin CL, Chang MC, Chen HM, Kok SH, Chang SH, et al. Differences in oral habit and lymphocyte subpopulation affect malignant transformation of patients with oral precancer. J Formos Med Assoc=Taiwan yi zhi. 2015. doi:10.​1016/​j.​jfma.​2015.​07.​017.
39.
Zurück zum Zitat Tabata T, Hazama S, Yoshino S, Oka M. Th2 subset dominance among peripheral blood T lymphocytes in patients with digestive cancers. Am J Surg. 1999;177(3):203–8.CrossRefPubMed Tabata T, Hazama S, Yoshino S, Oka M. Th2 subset dominance among peripheral blood T lymphocytes in patients with digestive cancers. Am J Surg. 1999;177(3):203–8.CrossRefPubMed
40.
Zurück zum Zitat Young M. Immunological phenotypes of premalignant oral lesions and the immune shifts with the development of head and neck cancer. Austin J Otolaryngol. 2014;1(2):7. Young M. Immunological phenotypes of premalignant oral lesions and the immune shifts with the development of head and neck cancer. Austin J Otolaryngol. 2014;1(2):7.
Metadaten
Titel
Immunophenotyping of patients with oral squamous cell carcinoma in peripheral blood and associated tumor tissue
verfasst von
Martin Grimm
Oliver Feyen
Heiko Hofmann
Peter Teriete
Thorsten Biegner
Adelheid Munz
Siegmar Reinert
Publikationsdatum
16.10.2015
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 3/2016
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-4224-2

Weitere Artikel der Ausgabe 3/2016

Tumor Biology 3/2016 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.